Quick Answer
Arcturus Therapeutics Holdings Inc. reported Total Revenue of $82.03 million for fiscal year 2025.
Arcturus Therapeutics Holdings Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $82.03M -46.1% |
$152.31M -8.7% |
$166.80M -19.0% |
$206.00M +1566.8% |
$12.36M +29.6% |
$9.54M -54.1% |
| Revenue (ASC 606) | $82.03M -46.1% |
$152.31M -8.7% |
$166.80M -19.0% |
$206.00M +1566.8% |
$12.36M +29.6% |
$9.54M -54.1% |
| Net Income | -$65.78M +18.7% |
-$80.94M -172.3% |
-$29.73M -417.9% |
$9.35M +104.6% |
-$203.67M -182.3% |
-$72.15M -177.6% |
| Diluted EPS | -$2.40 +20.0% |
-$3.00 -167.9% |
-$1.12 -420.0% |
$0.35 +104.5% |
-$7.74 | — |
| Total Assets | $271.15M -21.2% |
$344.07M -19.9% |
$429.40M -4.7% |
$450.39M +14.7% |
$392.81M -17.6% |
$476.46M +480.0% |
| Cash and Equivalents | $230.91M -2.6% |
$237.03M -18.8% |
$292.00M -25.5% |
$391.88M +5.8% |
$370.49M -20.0% |
$462.89M +548.7% |
| Long-Term Debt | — | — | — | — | $40.63M +193.5% |
$13.85M -7.7% |
| Stockholders Equity | $213.99M -11.2% |
$240.98M -13.5% |
$278.51M +3.0% |
$270.31M +18.4% |
$228.21M -42.5% |
$396.55M +1437.5% |
| R&D Expense | $112.21M -42.5% |
$195.16M +1.6% |
$192.13M +30.0% |
$147.75M -15.0% |
$173.76M +200.4% |
$57.85M +72.0% |
| Operating Income | -$76.26M +20.3% |
-$95.67M -22.3% |
-$78.20M -742.2% |
$12.18M +106.0% |
-$202.85M -183.6% |
-$71.52M -180.3% |
| Shares Outstanding | 28.41M +5.2% |
27.00M +0.6% |
26.83M +1.0% |
26.55M +0.7% |
26.37M +0.7% |
26.19M +73.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $17.15M | -58.8% | -39.4% |
| Revenue (ASC 606) | September 30, 2025 | $17.15M | -58.8% | -39.4% |
| Net Income | September 30, 2025 | -$13.45M | -94.8% | -46.5% |
| Diluted EPS | September 30, 2025 | -$0.49 | -88.5% | -44.1% |
| Total Assets | September 30, 2025 | $282.34M | -23.8% | -8.7% |
| Cash and Equivalents | September 30, 2025 | $180.36M | -24.0% | -8.2% |
| Long-Term Debt | March 31, 2025 | $15.00M | — | -25.0% |
| Stockholders Equity | September 30, 2025 | $224.56M | -14.2% | -2.8% |
| R&D Expense | September 30, 2025 | $23.27M | -40.6% | -21.3% |
| Operating Income | September 30, 2025 | -$16.51M | -53.8% | -42.1% |
| Shares Outstanding | September 30, 2025 | 27.23M | +0.6% | +0.3% |
- Arcturus Therapeutics Holdings Inc. reported Total Revenue of $82.03 million for fiscal year 2025.
- Arcturus Therapeutics Holdings Inc. showed a decrease of -46.1% in Total Revenue compared to the prior fiscal year.
- Arcturus Therapeutics Holdings Inc. reported Revenue (ASC 606) of $82.03 million for fiscal year 2025.
- Arcturus Therapeutics Holdings Inc. showed a decrease of -46.1% in Revenue (ASC 606) compared to the prior fiscal year.
- Arcturus Therapeutics Holdings Inc. reported Net Income of -$65.78 million for fiscal year 2025.
- Arcturus Therapeutics Holdings Inc. showed an increase of +18.7% in Net Income compared to the prior fiscal year.
- Arcturus Therapeutics Holdings Inc. reported Diluted EPS of $2.40 per share (loss) for fiscal year 2025.
- Arcturus Therapeutics Holdings Inc. showed an increase of +20.0% in Diluted EPS compared to the prior fiscal year.
- Arcturus Therapeutics Holdings Inc. reported Total Assets of $271.15 million for fiscal year 2025.
- Arcturus Therapeutics Holdings Inc. showed a decrease of -21.2% in Total Assets compared to the prior fiscal year.
- Arcturus Therapeutics Holdings Inc. reported Cash and Equivalents of $230.91 million for fiscal year 2025.
- Arcturus Therapeutics Holdings Inc. showed a decrease of -2.6% in Cash and Equivalents compared to the prior fiscal year.
- Arcturus Therapeutics Holdings Inc. reported Long-Term Debt of $40.63 million for fiscal year 2021.
- Arcturus Therapeutics Holdings Inc. showed an increase of +193.5% in Long-Term Debt compared to the prior fiscal year.
- Arcturus Therapeutics Holdings Inc. reported Stockholders Equity of $213.99 million for fiscal year 2025.
- Arcturus Therapeutics Holdings Inc. showed a decrease of -11.2% in Stockholders Equity compared to the prior fiscal year.
- Arcturus Therapeutics Holdings Inc. reported R&D Expense of $112.21 million for fiscal year 2025.
- Arcturus Therapeutics Holdings Inc. showed a decrease of -42.5% in R&D Expense compared to the prior fiscal year.
- Arcturus Therapeutics Holdings Inc. reported Operating Income of -$76.26 million for fiscal year 2025.
- Arcturus Therapeutics Holdings Inc. showed an increase of +20.3% in Operating Income compared to the prior fiscal year.
- Arcturus Therapeutics Holdings Inc. reported Shares Outstanding of 28.41 million shares for fiscal year 2025.
- Arcturus Therapeutics Holdings Inc. showed an increase of +5.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: